Voxelotor May Reduce Severity and Number of Leg Ulcers, Trial Analysis Suggests

Voxelotor can reduce the severity of existing leg ulcers and the incidence of new ones in people with sickle cell disease (SCD), new clinical trial results suggest. The findings detailed by the treatment’s developer, Global Blood Therapeutics (GBT), are being presented at the 13th Annual Academy for Sickle Cell and Thalassemia…

Voxelotor Before FDA for Approval as Possible Disease-modifying Treatment for Sickle Cell

The U.S. Food and Drug Administration (FDA) is giving priority review, as requested, to Global Blood Therapeutics‘ application to approve voxelotor as a treatment for sickle cell disease (SCD). Voxelotor, formerly known as GBT440, is as an oral and once daily potential sickle cell therapy. It works by…

Voxelotor Can Promote Long-Term Benefits in Teens, Adults with SCD, Latest Clinical Data Show

Global Blood Therapeutics’ lead therapeutic candidate voxelotor can induce rapid, robust, and sustained improvements in the amount of hemoglobin in adolescents and adults with sickle cell disease (SCD), according to interim results from the first part of a Phase 3 trial. The latest results of GBT’s clinical…